Matthew Wiley
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Matthew Wiley
BioXcel Therapeutics, Inc. reported in an 8-K filed October 9, 2024 that Matthew Wiley resigned as Senior Vice President and Chief Commercial Officer, effective October 2, 2024. The proxy statement of BioXcel Therapeutics, Inc. reports total compensation of $1,264,394 for Matthew Wiley in fiscal 2023, including a base salary of $445,200. Disclosed compensation is on record for 2 fiscal years.
“on September 19, 2024, Matthew Wiley, Senior Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the "Company"), and the Company agreed that Mr. Wiley would cease his employment with the Company, effective October 2, 2024 (the "Separation Date") and would serve as a consultant for a period of time thereafter.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
BioXcel Therapeutics, Inc. (BTAIQ)
Source not stated
Start not stated–2024-10-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | BioXcel Therapeutics, Inc. (BTAIQ) | SVP and Chief Commercial Officer | $445,200 | $1,264,394 |
| 2022 | BioXcel Therapeutics, Inc. (BTAIQ) | SVP and Chief Commercial Officer | $402,500 | $1,927,697 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.